1. Shan W, Ning C, Luo X, Zhou Q, Gu C, Zhang Z, et al. Hyperinsulinemia is associated with endometrial hyperplasia and disordered proliferative endometrium: a prospective cross-sectional study. Gynecol Oncol. 2014; 132:606–610.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Mitsuhashi A, Uehara T, Hanawa S, Shozu M. Prospective evaluation of abnormal glucose metabolism and insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer. Support Care Cancer. 2017; 25:1495–1501.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Ning C, Xie B, Zhang L, Li C, Shan W, Yang B, et al. Infiltrating macrophages induce ERα expression through an IL17A-mediated epigenetic mechanism to sensitize endometrial cancer cells to estrogen. Cancer Res. 2016; 76:1354–1366.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer. 2009; 19:249–252.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, et al. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol. 2014; 133:229–233.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013; 49:868–874.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez FR. Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis. Eur J Cancer. 2015; 51:2747–2758.
8. Merritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, et al. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes Control. 2016; 27:737–748.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012; 125:751–757.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Yang YF, Liao YY, Liu XL, Su SG, Li LZ, Peng NF. Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol Oncol. 2015; 139:419–423.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet. 2016; 132:34–38.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Yazıcı D, Sezer H. Insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol. 2017; 960:277–304.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Greenfield JR, Campbell LV. Insulin resistance and obesity. Clin Dermatol. 2004; 22:289–295.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Sun W, Lu J, Wu S, Bi Y, Mu Y, Zhao J, et al. Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women. Am J Cancer Res. 2016; 6:2334–2344.
15. Piltonen TT, Chen JC, Khatun M, Kangasniemi M, Liakka A, Spitzer T, et al. Endometrial stromal fibroblasts from women with polycystic ovary syndrome have impaired progesterone-mediated decidualization, aberrant cytokine profiles and promote enhanced immune cell migration in vitro. Hum Reprod. 2015; 30:1203–1215.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4:579–591.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Simó R, Sáez-López C, Barbosa-Desongles A, Hernández C, Selva DM. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab. 2015; 26:376–383.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Simó R, Saez-Lopez C, Lecube A, Hernandez C, Fort JM, Selva DM. Adiponectin upregulates SHBG production: molecular mechanisms and potential implications. Endocrinology. 2014; 155:2820–2830.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Lv QY, Xie BY, Yang BY, Ning CC, Shan WW, Gu C, et al. Increased TET1 expression in inflammatory microenvironment of hyperinsulinemia enhances the response of endometrial cancer to estrogen by epigenetic modulation of GPER. J Cancer. 2017; 8:894–902.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Xie BY, Lv QY, Ning CC, Yang BY, Shan WW, Cheng YL, et al. TET1-GPER-PI3K/AKT pathway is involved in insulin-driven endometrial cancer cell proliferation. Biochem Biophys Res Commun. 2017; 482:857–862.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Patel BG, Rudnicki M, Yu J, Shu Y, Taylor RN. Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet Gynecol Scand. 2017; 96:623–632.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Wu Y, Starzinski-Powitz A, Guo SW. Prolonged stimulation with tumor necrosis factor-alpha induced partial methylation at PR-B promoter in immortalized epithelial-like endometriotic cells. Fertil Steril. 2008; 90:234–237.
23. Pierce S, Roberson AE, Hyatt K, Singleton K, Deschamps D, Myers DA. Interaction between progesterone and interleukin-1β in modulating progesterone receptor expression and the inflammatory phenotype in human cervical fibroblasts. Reprod Sci. Forthcoming. 2017.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Al-Sabbagh M, Lam EW, Brosens JJ. Mechanisms of endometrial progesterone resistance. Mol Cell Endocrinol. 2012; 358:208–215.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M, Mesiano S. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015; 21:155–173.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016; 27:262–266.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Li X, Guo YR, Lin JF, Feng Y, Billig H, Shao R. Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance. J Cancer. 2014; 5:173–181.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Shan W, Wang C, Zhang Z, Gu C, Ning C, Luo X, et al. Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia. J Gynecol Oncol. 2014; 25:214–220.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012; 207:266.e1–266.12.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012; 125:477–482.
31. Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer. 2015; 25:1010–1014.
![crossref](/image/icon/bnr_ref_cross.gif)
32. De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G, et al. Hysteroscopic resection in fertility-sparing surgery for atypical hyperplasia and endometrial cancer: safety and efficacy. J Minim Invasive Gynecol. 2015; 22:1178–1182.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Arendas K, Aldossary M, Cipolla A, Leader A, Leyland NA. Hysteroscopic resection in the management of early-stage endometrial cancer: report of 2 cases and review of the literature. J Minim Invasive Gynecol. 2015; 22:34–39.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010; 93:1286–1289.
![crossref](/image/icon/bnr_ref_cross.gif)